Display options
Share it on

Transplant Res. 2012 Sep 28;1(1):15. doi: 10.1186/2047-1440-1-15.

Generation of myeloid-derived suppressor cells using prostaglandin E2.

Transplantation research

Nataša Obermajer, Pawel Kalinski

Affiliations

  1. Departments of Surgery, University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA, 15213, USA. [email protected].

PMID: 23369567 PMCID: PMC3560989 DOI: 10.1186/2047-1440-1-15

Abstract

Myeloid-derived suppressor cells (MDSCs) are natural immunosuppressive cells and endogenous inhibitors of the immune system. We describe a simple and clinically compatible method of generating large numbers of MDSCs using the cultures of peripheral blood-isolated monocytes supplemented with prostaglandin E2 (PGE2). We observed that PGE2 induces endogenous cyclooxygenase (COX)2 expression in cultured monocytes, blocking their differentiation into CD1a+ dendritic cells (DCs) and inducing the expression of indoleamine 2,3-dioxygenase 1, IL-4Rα, nitric oxide synthase 2 and IL-10 - typical MDSC-associated suppressive factors. The establishment of a positive feedback loop between PGE2 and COX2, the key regulator of PGE2 synthesis, is both necessary and sufficient to promote the development of CD1a+ DCs to CD14+CD33+CD34+ monocytic MDSCs in granulocyte macrophage colony stimulating factor/IL-4-supplemented monocyte cultures, their stability, production of multiple immunosuppressive mediators and cytotoxic T lymphocyte-suppressive function. In addition to PGE2, selective E-prostanoid receptor (EP)2- and EP4-agonists, but not EP3/1 agonists, also induce the MDSCs development, suggesting that other activators of the EP2/4- and EP2/4-driven signaling pathway (adenylate cyclase/cAMP/PKA/CREB) may be used to promote the development of suppressive cells. Our observations provide a simple method for generating large numbers of MDSCs for the immunotherapy of autoimmune diseases, chronic inflammatory disorders and transplant rejection.

References

  1. Int J Cancer. 2012 Mar 1;130(5):1109-19 - PubMed
  2. Nat Immunol. 2000 Dec;1(6):510-4 - PubMed
  3. J Immunol. 1997 Jul 1;159(1):28-35 - PubMed
  4. Nat Med. 2003 May;9(5):562-7 - PubMed
  5. J Clin Invest. 2010 Jul;120(7):2486-96 - PubMed
  6. Int Immunopharmacol. 2011 Jul;11(7):789-93 - PubMed
  7. Annu Rev Immunol. 2007;25:267-96 - PubMed
  8. J Exp Med. 2005 Oct 3;202(7):931-9 - PubMed
  9. J Leukoc Biol. 2010 Nov;88(5):839-48 - PubMed
  10. Blood. 2010 Dec 16;116(25):5738-47 - PubMed
  11. J Immunol. 2010 Nov 15;185(10):5828-34 - PubMed
  12. J Biol Chem. 2001 Aug 24;276(34):31720-31 - PubMed
  13. Stem Cells. 2010 Mar 31;28(3):620-32 - PubMed
  14. J Exp Med. 2007 Jun 11;204(6):1463-74 - PubMed
  15. Cancer Res. 2007 May 1;67(9):4507-13 - PubMed
  16. Am J Transplant. 2009 Sep;9(9):2034-47 - PubMed
  17. J Exp Med. 2000 Jun 19;191(12):2131-44 - PubMed
  18. Prostate. 2010 Mar 1;70(4):443-55 - PubMed
  19. J Immunol. 2005 Oct 1;175(7):4583-92 - PubMed
  20. Nat Rev Immunol. 2005 Aug;5(8):641-54 - PubMed
  21. J Immunol. 2000 Jan 1;164(1):361-70 - PubMed
  22. Immunity. 2010 Jun 25;32(6):790-802 - PubMed
  23. J Immunol. 2000 Apr 1;164(7):3596-9 - PubMed
  24. Cancer Immunol Immunother. 2011 Sep;60(9):1269-79 - PubMed
  25. Gastroenterology. 2006 Aug;131(2):510-24 - PubMed
  26. Hum Immunol. 2010 Nov;71(11):1061-6 - PubMed
  27. Mucosal Immunol. 2010 Nov;3(6):578-93 - PubMed
  28. J Immunol. 2010 Aug 15;185(4):2273-84 - PubMed
  29. Nat Rev Immunol. 2009 Mar;9(3):162-74 - PubMed
  30. Cancer Res. 2011 Dec 15;71(24):7463-70 - PubMed
  31. Cancer Res. 1998 Mar 15;58(6):1208-16 - PubMed
  32. Transplantation. 2008 Oct 27;86(8):1125-34 - PubMed
  33. J Biol Chem. 2007 Apr 20;282(16):11613-7 - PubMed
  34. J Immunol. 2011 Aug 1;187(3):1157-65 - PubMed
  35. Eur J Immunol. 2010 Jan;40(1):22-35 - PubMed
  36. Nat Rev Immunol. 2004 Dec;4(12):941-52 - PubMed
  37. Autoimmun Rev. 2010 Nov;10(1):8-17 - PubMed
  38. Transplant Res. 2012 Sep 28;1(1):17 - PubMed
  39. Neuro Oncol. 2011 Jun;13(6):591-9 - PubMed
  40. J Clin Oncol. 2007 Jun 20;25(18):2546-53 - PubMed
  41. J Immunother. 2001 Nov-Dec;24(6):431-46 - PubMed
  42. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s - PubMed
  43. EMBO J. 2002 Sep 16;21(18):4831-40 - PubMed
  44. J Immunol. 2007 Oct 15;179(8):5071-81 - PubMed
  45. J Immunol. 2009 May 1;182(9):5693-701 - PubMed
  46. J Immunol. 2007 Oct 15;179(8):5228-37 - PubMed
  47. Blood. 1998 Dec 1;92(11):4150-66 - PubMed
  48. J Immunol. 2008 Jun 15;180(12):7898-906 - PubMed
  49. Transplant Res. 2012 Sep 28;1(1):14 - PubMed
  50. Clin Immunol. 2008 Dec;129(3):471-81 - PubMed
  51. Nat Immunol. 2010 Aug;11(8):647-55 - PubMed
  52. Transplant Res. 2012 Sep 28;1(1):16 - PubMed
  53. J Immunol. 2005 Feb 15;174(4):1841-50 - PubMed
  54. Cancer J. 2010 Jul-Aug;16(4):318-24 - PubMed
  55. Blood. 2011 Nov 17;118(20):5498-505 - PubMed
  56. Nat Rev Immunol. 2004 Oct;4(10):762-74 - PubMed
  57. Hepatology. 2009 Sep;50(3):799-807 - PubMed
  58. Science. 2001 Jul 13;293(5528):253-6 - PubMed
  59. J Immunol. 2007 Jul 15;179(2):977-83 - PubMed
  60. Cancer Res. 2006 Sep 15;66(18):9290-8 - PubMed
  61. Gastroenterology. 2008 Sep;135(3):871-81, 881.e1-5 - PubMed
  62. J Immunol. 2012 Jan 1;188(1):21-8 - PubMed
  63. Gastroenterology. 2008 Jul;135(1):234-43 - PubMed
  64. Blood. 1998 Dec 15;92(12):4778-91 - PubMed
  65. J Immunol. 2009 Jan 1;182(1):240-9 - PubMed
  66. J Leukoc Biol. 2010 Nov;88(5):827-9 - PubMed
  67. Curr Opin Immunol. 2011 Oct;23(5):692-7 - PubMed
  68. Trends Immunol. 2011 Jan;32(1):19-25 - PubMed

Publication Types